Medovex Corp. Announces $8.0 M IPO
Sichenzia Ross Friedman Ference LLP Represents Medovex Corp. in $ 8.0M Initial Public Offering
New York, NY – December 29, 2014 – Global Newswire – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that the Firm has represented Medovex Corporation (NASDAQ: MDVXU), a producer of medical device products, in an initial public offering of 1,391,305 units. Each unit consisted of one share of common stock and one Series A Warrant at a price of $5.75 per unit. The IPO resulted in gross proceeds of $8,000,003 to the Company. The IPO was underwritten by Laidlaw & Company (UK) LTD.
The units trade on the NASDAQ Capital Markets under the symbol “MDVXU” and the common stock and warrants will trade under the symbols “MDVX” and “MDVXW”, respectively on separation.
Medovex is developing and commercializing the DenerVex® device, which is used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. In 2013, Medovex entered into a Co-Development Agreement with Dr. James Andrews, a renowned orthopedic surgeon who also is a director of the Company. Additionally Medovex intends to seek out acquisition opportunities through its world class Board of Directors which also includes Steve Gorlin, Major General C.A. “Lou” Hennies and Dr. Scott M. W. Haufe.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Harvey Kesner, Arthur S. Marcus and Associate Marc J. Adesso.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)